Get The Facts In Observance Of National Multiple Sclerosis Awareness WeekYou might see people wearing orange this week for National Multiple Sclerosis Awareness Week. More than 2 million people suffer from Multiple Sclerosis (MS) around the world.
Join A Local Family To Battle Multiple SclerosisFighting a chronic disease often affects the entire family — but for one metro Detroit woman, the battle has become even more personal.
Woodhaven Woman Wants To End Own Life To Donate OrgansSherri Muhzer, 43, has been housebound for 11 years due to her condition.
Thousands Will Get Down And Dirty In "Muckfest" To Benefit MS Thousands of people are expected to converge on Belle Isle Saturday, where they will be getting down and dirty ... literally ... for multiple sclerosis (MS).
Positively Minnesota: Harding Shines, InspiresMinnesota Wild goaltender doesn't want to be considered the NHL's only player with multiple sclerosis, he just wants to be recognized for stopping the puck.
Wayne State Research Team Finds Possible Clue To Progression Of MSWayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis may play a role in the disease’s progression. The finding could lead to new targeted therapies for MS treatment.
Walk For MS Looks To Raise More Than $200KMore than 1,000 people took part in the Multiple Sclerosis walk in downtown Detroit.
Synthetic Biologics Launches Free Investor Relations Mobile ApplicationSynthetic Biologics Inc. (NYSE Amex: SYN) Thursday announced the release of its investor relations mobile iPhone App, called the "SYN IR" App, now available for free at the Apple App Store on the iPhone or iPad or at http://bit.ly/I9xDpW.
Synthetic Biologics Reports 2011 Year End Financial ResultsThe pharmaceutical startup Synthetic Biologics Inc. (NYSE Amex: SYN) reported a larger loss for the year ended Dec. 31, but also a host of promising operational highlights.
Synthetic Biologics Announces Completion Of Enrollment In Trial Of MS DrugSynthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and medicines for serious illnesses, announced that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics' proprietary oral formulation of estriol (Trimesta) for the treatment of relapsing-remitting multiple sclerosis.
WSU Researcher's Model Will Target Causes Of Everyday MS SymptomsMost research on multiple sclerosis focuses on the disease's infrequent-but-debilitating consequences. Now, a Wayne State University researcher is targeting MS's more annoying everyday symptoms like difficulty hearing or remembering things.
Adeona Names New Managers, Eyes Name ChangeAdeona Pharmaceuticals Inc. has swapped bosses as it continues testing new drugs for multiple sclerosis, fibromyalgia and Lou Gehrig's disease. It's also considering a new business focus and a name change.